Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGR in Untreated Follicular Lymphoma
NCT07299149Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in follicular lymphoma (FL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Objective Response Rate up to 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07299149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299149.